This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Written by Kim Callender, NP, FNP-BC·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed July 12, 2026·Methodology v1.0

Compounded GLP-1 legality in 2026: the timeline that closed the market

Quick answer

Routine compounding of semaglutide and tirzepatide is no longer lawful on the basis that created the market. The shortage exception closed when the FDA declared both shortages resolved, and enforcement discretion ended for every class of compounder between February 18 and May 22, 2025. On April 30, 2026 the FDA proposed closing the remaining 503B route as well.

The exact timeline

FDA compounding timeline for semaglutide and tirzepatide — every date sourced to an FDA order or court decision
Date	What happened	Why it matters
March 2022	Semaglutide (Wegovy) added to the FDA drug shortage list.	Shortage begins — the legal window for compounding opens.
August 2022	Ozempic (semaglutide) added to the shortage list.
December 15, 2022	Tirzepatide (Mounjaro, Zepbound) added to the shortage list.	Compounded tirzepatide becomes lawful under the shortage exception.
October 2, 2024	FDA declares the tirzepatide shortage resolved.	The legal basis for compounding tirzepatide as an 'essentially a copy' drug begins to close.
December 19, 2024	FDA reaffirms the tirzepatide resolution in a declaratory order.	Sets a 60-day (503A) / 90-day (503B) transition.
February 18, 2025	503A enforcement discretion for tirzepatide ENDS.	State-licensed pharmacies must stop compounding tirzepatide copies.
February 21, 2025	FDA removes semaglutide from the shortage list.
March 19, 2025	503B enforcement discretion for tirzepatide ENDS.	Outsourcing facilities must stop compounding tirzepatide copies.
April 22, 2025	503A enforcement discretion for semaglutide ENDS.
April 24, 2025	Court denies the Outsourcing Facilities Association's injunction (semaglutide).	OFA v. FDA, N.D. Tex. — FDA's determination stands.
May 7, 2025	Court upholds FDA on tirzepatide in OFA v. FDA.	The shortage-exception route is closed for both molecules.
May 22, 2025	503B enforcement discretion for semaglutide ENDS.	All shortage-based compounding of both molecules is now outside enforcement discretion.
April 30, 2026	FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.	Finding: no clinical need for outsourcing facilities to compound them from bulk. Comment period closed June 29, 2026.

The rule that governs everything

The "essentially a copy" rule

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act bar compounders from producing drugs that are essentially a copy of a commercially available FDA-approved product. While a drug sits on the FDA shortage list, that bar is lifted. Once the shortage is resolved, it snaps back.

Why every provider suddenly sells "personalized" and "microdose" doses

What is still lawful

What is not lawful is what built the industry: mass-producing standard-strength copies of Wegovy and Zepbound and selling them as a cheaper equivalent.

Enforcement and litigation

Enforcement and litigation riskEli Lilly and Novo Nordisk are actively litigating against telehealth companies, medical spas and compounding pharmacies marketing compounded copies, and have sent cease-and-desist letters across the sector. Enforcement risk is not theoretical, and it falls on the provider — but a provider that is forced to stop mid-course leaves the patient without continuity of supply.

What this means for you as a patient

The risk you carry is not legal — it is continuity. If your pharmacy is forced to stop, your supply stops, potentially mid-titration. Ask any provider what their contingency is, and note that the brand price collapse has narrowed the reason to take that risk at all.

The finding most comparison sites will not printThe economic case for compounded GLP-1 has narrowed sharply, and almost no comparison site says so. In 2023 the choice was roughly $1,000+/month for brand versus $150–$300 for compounded — a gap wide enough to justify real regulatory risk. As of July 12, 2026, brand Zepbound is $299–$449 through LillyDirect, brand Wegovy is $349 (or $149 for the oral tablet) through NovoCare, and both drop to roughly $25 with commercial coverage. Meanwhile compounded programs advertise $99–$299.

For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.

Monitoring and laboratory work

During treatment, tolerance should be reviewed at each dose escalation rather than automatically. Persistent vomiting, severe abdominal pain radiating to the back, or signs of gallbladder disease warrant prompt clinical contact rather than a message to a chat widget.

Questions to ask your clinician

Given my history, is a GLP-1 appropriate for me at all — and is there a reason it might not be?
What baseline laboratory work will you order before I start?
What is the target dose, and how quickly will we escalate to it?
What side effects should make me call you rather than wait?
What is the plan for maintenance, and what happens if I stop?
Will I see the same clinician at follow-up, or a different one each time?

Questions to ask about the pharmacy

The pharmacy matters more than the telehealth brand on the front of the website. The telehealth company arranges the consultation; the pharmacy makes the medicine you inject.

Which specific pharmacy will fill my prescription? Not "our network" — the name of the facility.
Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and a company can use both for different products.
In which state is it licensed, and can I look up the licence? State boards of pharmacy publish licensee databases.
What is the exact salt form and concentration? Semaglutide sodium and semaglutide acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has said they are not appropriate for compounding.
Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself, which is the most common source of the dosing errors behind reported adverse events.
Will you provide a certificate of analysis?
Has the pharmacy received any FDA warning letter or state board action?

A provider that answers all seven in writing is demonstrating something real. A provider that will not name its pharmacy has given you an answer, whether it intended to or not.

What happens when you stop

Storage and handling

How to verify any of this yourself

You should not take our word for a price, and you do not have to. Every figure here can be checked in a few minutes.

Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
Ask what the highest dose costs. By email or chat, so you have it in writing.
Ask about early cancellation before you commit to a plan longer than a month.
Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.

If a provider will not answer questions 4 or 5 in writing, that is itself information.

Who is actually who: the entities in this transaction

The single biggest source of confusion in telehealth medicine is that people assume one company is doing all of it. Usually four or five separate entities are involved, with different regulators and different duties to you.

The entities behind an online prescription, and what each is responsible for
Entity	What it is	Regulated by	What it is NOT
Telehealth company	The website you sign up on. Arranges the consultation, handles billing and logistics.	State corporate practice rules; FTC for advertising	Not a pharmacy. Does not make your medicine.
Prescribing clinician	The licensed physician, NP or PA who evaluates you and writes the prescription.	Their state medical or nursing board	Not employed by the pharmacy. Must exercise independent judgement.
503A compounding pharmacy	A state-licensed pharmacy compounding for an individual patient against a specific prescription.	State board of pharmacy; FDA for some provisions	Not FDA-approved. Products are not reviewed before marketing.
503B outsourcing facility	An FDA-registered facility that may compound in bulk without patient-specific prescriptions.	FDA, including cGMP inspection	Still not making FDA-approved products.
Manufacturer	Eli Lilly, Novo Nordisk. Makes the FDA-approved branded drug.	FDA — full premarket approval	Not involved in compounded products at all.

Two phrases to distrust immediatelyThere is no such thing as an 'FDA-approved pharmacy'. That phrase appears in marketing and it is meaningless. A pharmacy can be state-licensed (503A) or FDA-registered (503B). Neither makes its compounded products FDA-approved — approval is something that happens to a drug, after clinical trials, not to a facility.

Equally: a provider's statement about which pharmacy it uses is a provider-reported relationship until someone verifies it. We label it that way, and so should you when you read it.

Eligibility, and who is likely to be declined

A licensed clinician decides whether treatment is appropriate. No website can promise you eligibility, and one that implies it should worry you.

Be honest on the intake form. The temptation to shade an answer to secure a prescription is understandable and it is a bad trade: the questions exist because the contraindications are real.

State availability, and why it varies

Limitations of this analysis

Every page on this site should tell you where it stops being reliable. This one stops here.

Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.

We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.

Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.

Frequently asked questions

Is compounded tirzepatide legal in 2026?

Not on the basis that made it a mass-market product. The shortage exception closed and enforcement discretion ended in early 2025. The remaining 503A route requires a prescriber-documented clinical difference for the individual patient, which is what 'personalized dosing' is.

Did compounded GLP-1 become permanently legal through 503A and 503B?

No. That claim, which appears on several comparison sites, is wrong. Federal law bars compounding drugs that are essentially copies of approved products, and the exception that suspended that bar ended with the shortages.

Could this change again?

Yes. Litigation is ongoing and the FDA's 503B bulks-list proposal was still in process after its June 29, 2026 comment deadline. Treat any page on this topic, including ours, as time-sensitive.

Sources

U.S. Food and Drug Administration — labels and safety communications.
Peer-reviewed clinical trials cited above.
Our methodology and medical review policy.

Spotted an error? Submit a correction.

SURMOUNT-1 — mean body-weight reduction by tirzepatide dose, 72 weeks

Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.

Adverse events: the figure almost every site gets wrong

FDA adverse-event reports for compounded semaglutide and tirzepatide

Source: FDA GLP-1 webpage, reporting 1,700+ adverse events associated with compounded semaglutide and tirzepatide as of May 21, 2026 — against the 775 total, Feb 2025 figures from February 2025 that almost every comparison site is still quoting. Reports are voluntary and do not establish causation, but the trend is the point.

1,700+ — not 775. We were wrong too, and we have corrected it.The adverse-event figure you have read elsewhere is out of date. Nearly every comparison site — and this site, until we rechecked — quotes 1,700+ reports for compounded semaglutide and 320 for compounded tirzepatide. Those are February 2025 figures.

As of 21 May 2026, the FDA reports having received more than 1,700 adverse events associated with compounded semaglutide and tirzepatide. That is more than double the figure still in circulation, in roughly fifteen months.

Adverse-event reports are voluntary, are not adjudicated, and do not by themselves establish causation. That caveat is real and we will not drop it. But a site that quotes the 2025 number in mid-2026 is not being cautious — it is being out of date, and in a direction that flatters the product it is paid to sell.

Tirzepatide + B12 is not tirzepatideA March 2026 study identified a previously unknown tirzepatide–B12 adduct in mass-compounded tirzepatide formulated with vitamin B12. An adduct is a new chemical entity formed when two molecules combine. This one does not exist in FDA-approved tirzepatide, and its safety has not been characterised.

This matters far beyond one study, because it exposes the flaw in the whole ‘personalized dosing’ defence. Adding B12 was one of the commonest ways compounders argued their product was not “essentially a copy” of the approved drug — a clinical difference that kept them inside the law. The finding shows that the additive did not merely differentiate the product on paper. It chemically changed it, into something nobody has tested in a human being.

What to do: if you are taking a compounded tirzepatide that contains B12 — and many do, often marketed as ‘tirzepatide + B12’ or ‘with methylcobalamin’ — ask your provider and your pharmacy, in writing, whether they have tested for adduct formation. Most will not have. That answer is itself information.

FDA: affordability is not a clinical needThe FDA has explicitly rejected the argument that this entire industry rests on.

In the 30 April 2026 Federal Register notice (docket 2026-08552), the agency stated that there is no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk — and went out of its way to clarify that supply and affordability are not what the statute means by clinical need.

In plain terms: there are FDA-approved products; they work; patients can be treated with them. Whether a patient can afford them is a different problem, with a different set of policy tools.

That single sentence does enormous work. Every compounded-GLP-1 marketing page in America is, at bottom, an affordability argument. The agency has now said, on the record, that affordability is not a legal basis for compounding these drugs. If you are choosing a compounded programme because it is cheaper, you should know that the regulator has explicitly said that reason does not count.